EMEA-002185-PIP02-17

Key facts

Active substance
Human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400)
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0284/2018
PIP number
EMEA-002185-PIP02-17
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
Treatment in haematopoietic stem cell transplantation in patients with severe combined immunodeficiency syndrome (SCID)
Route(s) of administration
Intravenous use
Contact for public enquiries
Taiga Biotechnologies, Inc

E-mail: refaeli@taigabiotech.com
Tel. +1 7208593547

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating